Improving the efficiency of treatment for stages III—IV prostate cancer
https://doi.org/10.17650/1726-9776-2007-3-1-45-49
Abstract
Objective: to evaluate the efficiency of various therapeutic modalities in patients with Stages III, IV prostate cancer (PC) concurrent with local hyperthermia (LH).
Materials and methods. The results of treatment were analyzed in 895 PC patients; out of them 743 had Stages III (49.9%) and IV (33.1%). The following treatments were performed: radiation, hormonal, hormonoradiation, and hormonoradiation treatment with thermoradiomodification. Therapeutic efficiency was evaluated by the cumulative cancer-specific survival rates.
Results. In the patients with Stage III PC receiving multimodality treatment, 5-year survival was 66.1%. In the group of patients where thermoradiomodification was added the survival reached 76.7%. Patients treated with radiotherapy and hormonotherapy had a survival rate of 60.4 and 55.2%, respectively. By year 10 of a follow-up, the survival rates were 47.9% in the hormonotherapy group and 42.5% in the hormonoradiotherapy group. In patients with locally advanced Stage IV PC, 5-year survival was 68.5, 66.4, and 52.9% after hormonoradiation therapy, radiotherapy, and hormonotherapy, respectively. The patients receiving treatment with thermoradiomodification fail to survive up to 5 years. 10-year cancer-specific survival following hormonoradiotherapy and hormonotherapy was 27.1 and 13.2%, respectively. In the patients with metastatic PC who had hormonotherapy, radiotherapy, complex treatment without and with thermoradiomodification, 5-year survival was 51.0, 45.3, 35.6, and 0%, respectively. As high as 7.7% of the patients, who have received hormonal therapy, survived up to 10 years.
Conclusion. Multimodality treatment is most effective in the management of Stages III and IV PC. Thermoradiomodification significantly improves the results of treatment for Stage III, but it should not be applied to patients with Stage IV. Radiotherapy is more effective in the first years of life, but further its efficiency becomes less. Hormonotherapy is most beneficial in disseminated cancer.
About the Authors
A. V. Vazhenin
Chelyabinsk Regional Cancer Dispensary
Russian Federation
Russian Federation
P. A. Karnaukh
Chelyabinsk Regional Cancer Dispensary
Russian Federation
Russian Federation
References
1. Трапезников Н.Н., Аксель Е.М. Заболеваемость злокачественными новообразованиями и смертность от них населения стран СНГ в 1997 г. М., 1999.
2. Brasso K., Iverson P. Prostate cancer in Denmark. Incidence, morbidity and mortality. Scand J Urol Nephrol Suppl 1999;203:29—33.
3. Kanamaru H., Arai Y., Akino H. et al. Long-term treatment results of elderly patients with prostate cancer in Japan: an analysis of prognostic factors. Jpn J Clin Oncol 1999;29(3):151—5.
4. Переверзев А.С., Коган М.И. Рак простаты. Харьков, Факт; 2004. c. 231.
5. Серняк Ю.П., Криштопа М.В. Консервативная терапия рака предстательной железы. Материалы пленума правления Российского общества урологов. Омск; 1999 г. c. 194—5.
6. Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. М.; 1999.
7. Бухаркин Б.В. Современные методы лечения местно-распространенного и диссеминированного рака предстательной железы: Автореф. дис. …док. мед. наук. М., 1995.
8. Виноградов В.М. Субтотальное облучение онкологических больных. С.-Пб.; 1993.
9. Голдобенко Г.В., Ткачев С.И. Рак предстательной железы. В кн.: Лучевая терапия злокачественных опухолей. М., Медицина; 1996. с. 319—29.
10. Гранов А.М., Винокуров В.Л. Лучевая терапия в онкогинекологии и онкоурологии. С.-Пб., Фолиант; 2002.
11. Кондратьева А.П. Лучевая терапия рака предстательной железы. Клин онкол 1999;1(1):17—21.
12. Ткачев С.И. Сочетанное применение лучевой терапии и локальной гипертермии в лечении местно-распространенных новообразований: Автореф. дис. … док. мед. наук. М.; 1994.
13. Ощепков В.Н., Дарий Е.В., Сивков А.В. и др. Трансректальная микроволновая гипертермия в комплексном лечении больных распространенным раком предстательной железы. Материалы пленума правления Российского общества урологов. Омск; 1999. с. 189—90.
14. Falk M.H., Issels R.D. Hyperthermia in oncology. Int J Hyperthermia 2001;17:1—18.
15. Osinsky S., Shidnia H. The 20th anniversary of the International Clinical Hyperthermia Society (ICHS): experimental and clinical experience. Exp Oncol 2000;22:95—6.
16. Nielsen O.S., Horsman M., Overgaard J. A future for hyperthermia in cancer treatment? Eur J Cancer 2001;37:1587—9.
17. Осинский С.П. Гипертермия в клинической онкологии: современное состояние проблем (по итогам 20-й ежегодной конференции Европейского общества гипертермической онкологии). Онкология 2002;4(4):288—92.
18. Abstracts Book of the 20th Annual Meeting of the European Society for Hyperthermic Oncology. Bergen, Norway, May 23—25, 2002.
19. Метелев В.В. Место лучевой терапии в комбинированном лечении больных с раком предстательной железы. Автореф. дис. … док. мед. наук. С.-П., 1995.
Review
For citations:
Vazhenin A.V., Karnaukh P.A. Improving the efficiency of treatment for stages III—IV prostate cancer. Cancer Urology. 2007;3(1):45-49. (In Russ.) https://doi.org/10.17650/1726-9776-2007-3-1-45-49
Views:
280
Email this article 